Regarding 177Lu-PSMA-617, the number of patients with metastatic castration-resistant prostate cancer, who are the targets of this treatment, is significantly higher than that of diseases historically targeted by nuclear medicine therapy, leading us to believe that the introduction of this treatment will mark a major turning point for nuclear medicine therapy in Japan. This evidence concerns the gene FOLH1 and prostate carcinoma.